TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00734474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study: NCT01041326

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Pre-operative Radiation to Prostate, SV, and Pelvic Lymph Nodes

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Pre-operative Radiation to Prostate, SV, and Pelvic Lymph Nodes

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Pre-operative Radiation to Prostate, SV, and Pelvic Lymph Nodes

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Pre-operative Radiation to Prostate, SV, and Pelvic Lymph Nodes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Patients will undergo evaluation by a surgeon for consideration of resection after completion of radiation therapy. If a surgical resection is possible, it is recommended that patients undergo surgery four to eight weeks after completion of radiation therapy. This surgical procedure will be performed by one of the standard accepted approaches.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Patients will undergo evaluation by a surgeon for consideration of resection after completion of radiation therapy. If a surgical resection is possible, it is recommended that patients undergo surgery four to eight weeks after completion of radiation therapy. This surgical procedure will be performed by one of the standard accepted approaches.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Patients will undergo evaluation by a surgeon for consideration of resection after completion of radiation therapy. If a surgical resection is possible, it is recommended that patients undergo surgery four to eight weeks after completion of radiation therapy. This surgical procedure will be performed by one of the standard accepted approaches.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Patients will undergo evaluation by a surgeon for consideration of resection after completion of radiation therapy. If a surgical resection is possible, it is recommended that patients undergo surgery four to eight weeks after completion of radiation therapy. This surgical procedure will be performed by one of the standard accepted approaches.
Study: NCT01130675

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: caffeinated coffee
Description: 8 oz. of caffeinated cofee/breakfast\&noon meal. No intervention for 2nd arm.
Study: NCT03740633

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: passive ankle pump motions on the day of surgery
Description: Passive ankle pump motions include flexion and extension, circumduction, which will be conducted by caregiver on the day of surgery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: active ankle pump motions and abdominal breathing training on the 1-3 day after the surgery
Description: Active ankle pump motions include flexion and extension, circumduction, which will be conducted by patient on the 1-3 day after the surgery. On the same time, the patient is given abdominal breathing training.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Regular care
Description: Regular post-operative care consists of compression stockings, anticoagulant and instructions of early mobilization

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Regular care
Description: Regular post-operative care consists of compression stockings, anticoagulant and instructions of early mobilization
Study: NCT03056404

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: additional blood sample

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: respiratory functional exploration
Study: NCT02050243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5ALA
Description: 20mg/kg of oral suspension of 5ALA
Study: NCT02513342

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endostar
Description: Endostar 30mg continuous intravenous injection pump,d1-d7；

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: d4 Docetaxel，75（mg/m2），iv；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: d4 Docetaxel，75（mg/m2），iv；

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: d4，cisplatin，75（mg/m2），iv；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: d4，cisplatin，75（mg/m2），iv；
Study: NCT01704846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 NA 40 mg capsule
Description: 3 capsules of BI 201335 NA 40 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 NA 40 mg capsule
Description: 3 capsules of BI 201335 NA 40 mg capsule
Study: NCT00678158

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity modulated radiation therapy
Description: Patients will be accrued at each dose level beginning at 22 Gy with increments of 2 Gy up to 28 Gy. Patients with a soft tissue mass, lymph nodes or focal bone metastases with lesions large enough to be imaged on CT scan will be accrued. Starting at 24 Gy, patients will be stratified in to 3 treatment categories: lesions involving bone, bowel, or spinal cord. Patients will be enrolled in each treatment category until 10 patients in that cohort reach an evaluable timepoint of 3 months post-RT. The maximum accrual is 20 for 22 Gy, and 90 (30 per treatment category) for each subsequent dose level (24-28 Gy). Some of these patients have participated in the optional FLT-PET scan portion of the study. Some of these patients have under gone an optional MRI scan which take place within one hour of the radiation treatment .

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity modulated radiation therapy
Description: Patients will be accrued at each dose level beginning at 22 Gy with increments of 2 Gy up to 28 Gy. Patients with a soft tissue mass, lymph nodes or focal bone metastases with lesions large enough to be imaged on CT scan will be accrued. Starting at 24 Gy, patients will be stratified in to 3 treatment categories: lesions involving bone, bowel, or spinal cord. Patients will be enrolled in each treatment category until 10 patients in that cohort reach an evaluable timepoint of 3 months post-RT. The maximum accrual is 20 for 22 Gy, and 90 (30 per treatment category) for each subsequent dose level (24-28 Gy). Some of these patients have participated in the optional FLT-PET scan portion of the study. Some of these patients have under gone an optional MRI scan which take place within one hour of the radiation treatment .

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity modulated radiation therapy
Description: Patients will be accrued at each dose level beginning at 22 Gy with increments of 2 Gy up to 28 Gy. Patients with a soft tissue mass, lymph nodes or focal bone metastases with lesions large enough to be imaged on CT scan will be accrued. Starting at 24 Gy, patients will be stratified in to 3 treatment categories: lesions involving bone, bowel, or spinal cord. Patients will be enrolled in each treatment category until 10 patients in that cohort reach an evaluable timepoint of 3 months post-RT. The maximum accrual is 20 for 22 Gy, and 90 (30 per treatment category) for each subsequent dose level (24-28 Gy). Some of these patients have participated in the optional FLT-PET scan portion of the study. Some of these patients have under gone an optional MRI scan which take place within one hour of the radiation treatment .
Study: NCT02874261

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole Body Periodic Acceleration
Description: oscillating bed that the subject will lie on 3 days a week for 45 minutes at 140 cycles per minute.
Study: NCT01265758

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged telemetric Full Disclosure ECG recording.
Description: Continuous Full Disclosure Telemetric ECG monitoring lasting 14 days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prolonged telemetric Full Disclosure ECG recording.
Description: Continuous Full Disclosure Telemetric ECG monitoring lasting 14 days
Study: NCT02104752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: 360 mg/day (divided into twice daily oral doses)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive, matched placebo (Sugar Pill)
Study: NCT01432158

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar 13
Description: This vaccine will be given to healthy adults without prior pneumococcal vaccination.
Study: NCT00912015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol OAD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol OAD
Study: NCT01432158

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax II
Description: This vaccine will be given to healthy adults without prior pneumococcal vaccination.
Study: NCT04242758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 MG
Description: SGLT2-inhibitor: Diabetic oral drug with diuretic properties

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 12.5mg
Description: Best known thiazide class diuretic.
Study: NCT04101123

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study: NCT01268345

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: blood glucose monitor
Description: Blood glucose monitor is used to monitor the blood glucose level of the human-being

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: blood glucose monitor
Description: Blood glucose monitor is used to monitor the blood glucose level of the human-being.
Study: NCT00664846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin / Clopidogrel, Atorvastatin / Simvastatin
Description: Standard Medical Management,including antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide) .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asprin / Clopidogrel, Atorvastatin / Simvastatin
Description: Antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary
Study: NCT03907007

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous electrical nerve stimulation
Description: Stimulation and medication at the same instant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous electrical nerve stimulation
Description: Stimulation is given without administering medication
Study: NCT02242162

Intervention type: PROCEDURE
Intervention: phrenic nerves magnetic stimulations
Study: NCT02210702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl Estradiol 35mcg/Norethindrone 1mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl Estradiol 20mcg/Norethindrone 1mg
Study: NCT00779571

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crispbread
Description: 8 week low calorie diet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Crispbread
Description: 8 week low calorie diet
Study: NCT04025905

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Cognition Training
Description: Evaluate the impact of the social cognition training on employment maintaining in transitional Workforce Assistance Facilities and Services.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Informations
Description: informations about work environment, social environment, stress management, sleep management, treatments
Study: NCT03613129

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CT38
Description: Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CT38
Description: Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CT38
Description: Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CT38
Description: Infusion
Study: NCT00857480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL972
Description: Single intravenous administration of 2 mg NRL972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL972
Description: Pre-treatment and co-treatment with 1 g Cloxacillin t.i.d. for three days from the morning of D-3 until the morning of Day D01 0:30 hour before the intravenous administration of NRL972.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL972
Description: Three week pre-treatment with daily doses of 500 mg b.i.d ursodeoxycholic acid from the morning of D-20 until the evening of Day D-1
Study: NCT03594331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose PvP001
Description: Low-dose PvP001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose PvP001
Description: Low-dose PvP001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose PvP001
Description: Low-dose PvP001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium-dose PvP001
Description: Medium-dose PvP001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium-dose PvP001
Description: Medium-dose PvP001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium-dose PvP001
Description: Medium-dose PvP001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose PvP001
Description: High-dose PvP001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose PvP001
Description: High-dose PvP001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose PvP001
Description: High-dose PvP001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 100 mL liquid with no drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 100 mL liquid with no drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 100 mL liquid with no drug
Study: NCT02873676

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutritional intervention
Description: The intervention is made up of nutrition supplements and dietary pattern modification, which includes whey 30g/d(plus three times every week),vitamin D 1000IU, omega-3 fatty acid (DHA1200mg and EPA 800mg)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resistance training program
Description: The training program involve warm-up exercise, muscle strength training and relaxing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle modification project
Description: Lifestyle modification project is made up of multi-dimensional intensive nutritional intervention and resistance training

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: The intervention involve dietary pattern modification and protein intake standardization
Study: NCT04310579

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone and Midazolam
Description: In one period subjects receive oxycodone 10-15 mg immediate release (IR) and placebo IV 1x per day.~In a second period (randomized cross-over), subjects receive midazolam 0.0375-0.075 mg/kg IV and oral placebo tablet 1x per day.~In a third period (randomized cross-over), subjects receive oxycodone 10-15 mg IR tablet and 0.0375-0.075 mg/kg midazolam IV 1x per day.~In a fourth period (randomized cross-over), subjects receive oral placebo tablet and placebo IV 1x per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone, Paroxetine, and Quetiapine
Description: In one period, subjects receive: oxycodone 10-15 mg IR tablet 1x per day and oral placebo 3x per day on Days 1 and 5; and oral placebo 3x per day on Days 2-4.~In a second period (randomized cross-over), subjects receive: oxycodone 10-15 mg IR tablet 1x per day, paroxetine 40 mg tablet 1x per day, and oral placebo 1x per day on Days 1 and 5; and paroxetine 40 mg tablet 1x per day and oral placebo 2x per day on Days 2-4.~In a third period (randomized cross-over), subjects receive: oxycodone 10-15 mg IR tablet 1x per day, quetiapine 50 mg tablet 2x per day, and oral placebo 1x per day on Day 1; quetiapine 100 mg (2x50 mg tablets) 2x per day and oral placebo 1x per day on Day 2; quetiapine 150 mg (3x50 mg tablets) 2x per day and oral placebo 1x per day on Day 3; quetiapine 200 mg (4x50 mg tablets) 2x per day and oral placebo 1x per day on Day 4; and quetiapine 200 mg (4x50 mg tablets) 1x per day and oral placebo 1x per day on Day 5.
Study: NCT02454205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: 600mg Linezolid po daily, reduced to 300mg po daily if toxicity occurs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: 400mg po daily for 2 weeks, followed by 200mg three times per week .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: 750mg (\<50kg) 1000mg (\>50kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrazinamide
Description: 1000-1750mg (40-50kg) 1750-2000mg (51-70kg) 2000-2500mg (71-90kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: 1000-1750mg (40-50kg) 1750-2000mg (51-70kg) 2000-2500mg (71-90kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: high dose Isoniazid 500mg (40-50kg) 750mg (51-70kg) 750-1000mg (71-90kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethionamide
Description: 15mg/kg (max 900mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethionamide
Description: 15mg/kg (max 900mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terizidone
Description: 750mg (40-70kg) 750-1000mg (71-90kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terizidone
Description: 750mg (40-70kg) 750-1000mg (71-90kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 400mg po daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kanamycin
Description: 500-750mg (40-50kg) 1000mg (51-90kg) intramuscular daily during 6-8 month intensive phase.
Study: NCT03700658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-46046
Description: TV-46046 will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-46046
Description: TV-46046 will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depo-subQ 104
Description: Depo-subQ 104 will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TV-46046 Placebo
Description: TV-46046 Placebo will be administered per schedule specified in the arm.
Study: NCT04148937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3475070
Description: Administered orally
Study: NCT00912015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol OAD

Intervention type: DRUG
Group type: OTHER
Intervention: Tramadol OAD 100mg
Study: NCT01741272

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sling
Description: Patients will use a sling for 6 weeks as per usual care. No active ROM allowed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No sling
Description: Patients may discontinue use of the sling as early as pain and comfort allow. Early active ROM is allowed for activities of daily living.
Study: NCT02167568

Intervention type: GENETIC
Intervention: Genetic

Intervention type: GENETIC
Intervention: Genetic
Study: NCT04076722

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress reactivity stimuli
Description: An evaluated speech task delivered to participants after baseline testing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress reactivity stimuli
Description: An evaluated speech task delivered to participants after baseline testing.